氯吡格雷用于急性冠状动脉综合征 - Suppr

Suppr

超能文献

Clopidogrel in acute coronary syndromes.

作者信息

Chua Doson, Ignaszewski Andrew

机构信息

St Paul's Hospital, Department of Pharmacy, Vancouver, BC V6Z 1Y6, Canada.

出版信息

BMJ. 2009 Apr 14;338:b1180. doi: 10.1136/bmj.b1180.

DOI:10.1136/bmj.b1180

PMID:19366756

Abstract

摘要

相似文献

Clopidogrel in acute coronary syndromes.氯吡格雷用于急性冠状动脉综合征

BMJ. 2009 Apr 14;338:b1180. doi: 10.1136/bmj.b1180.

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.普拉格雷：新药。血管成形术和支架置入术后：继续使用阿司匹林+氯吡格雷。

Prescrire Int. 2009 Oct;18(103):193-5.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.氯吡格雷和阿司匹林在急性冠脉综合征中的剂量比较。

N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475.

The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.接受直接血管成形术的ST段抬高型心肌梗死患者的氯吡格雷负荷剂量。

Am J Emerg Med. 2010 Mar;28(3):382-3. doi: 10.1016/j.ajem.2009.11.017.

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.普拉格雷对接受经皮冠状动脉介入治疗的急性冠脉综合征患者的早期和晚期获益：TRITON-TIMI 38（通过普拉格雷优化血小板抑制评估治疗转归改善的试验-心肌梗死溶栓38）分析

J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002.

The safety of clopidogrel.氯吡格雷的安全性。

Expert Opin Drug Saf. 2011 Jan;10(1):85-95. doi: 10.1517/14740338.2011.532485. Epub 2010 Nov 20.

[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].[急性冠状动脉综合征——12个月期间双重血小板聚集抑制的长期保护作用]

MMW Fortschr Med. 2008 Oct 16;150(42):52-3.

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.与氯吡格雷相比，可逆性口服P2Y12受体拮抗剂AZD6140对急性冠脉综合征患者血小板聚集的抑制作用。

J Am Coll Cardiol. 2007 Nov 6;50(19):1852-6. doi: 10.1016/j.jacc.2007.07.058. Epub 2007 Oct 23.

[Acute coronary syndrome: when an indication for clopidogrel?].

Dtsch Med Wochenschr. 2006 Dec 15;131(50):2864. doi: 10.1055/s-2006-957214.

Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.药物洗脱支架置入术后双重抗血小板治疗应持续超过1年吗？：药物洗脱支架置入术后双重抗血小板治疗应持续超过1年，最好是无限期持续。

Circ Cardiovasc Interv. 2008 Dec;1(3):217-25. doi: 10.1161/CIRCINTERVENTIONS.108.811380.

引用本文的文献

For Patients Needing Oral Anticoagulation for Atrial Fibrillation and Dual Antiplatelet Therapy after Percutaneous Coronary Intervention, Is Double Therapy Preferred over Triple Therapy?对于因心房颤动需要口服抗凝治疗且在经皮冠状动脉介入治疗后需要双重抗血小板治疗的患者，双重治疗是否优于三联治疗？

Can J Hosp Pharm. 2019 Nov-Dec;72(6):464-467. Epub 2019 Dec 1.

New antiplatelet agents for cardiovascular disease.用于心血管疾病的新型抗血小板药物。

CMAJ. 2013 Nov 5;185(16):1405-11. doi: 10.1503/cmaj.130033. Epub 2013 Sep 9.

Clopidogrel and proton pump inhibitors: a new drug interaction?

Can J Hosp Pharm. 2010 Jan;63(1):47-50. doi: 10.4212/cjhp.v63i1.869.

Integrins as therapeutic targets: lessons and opportunities.整合素作为治疗靶点：经验与机遇。

Nat Rev Drug Discov. 2010 Oct;9(10):804-20. doi: 10.1038/nrd3266.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验